The Effect of Web-based Education Given to Parents on Children's Internet Gaming Disorder

March 23, 2023 updated by: Meryem MUTLU, Mersin University

The Effect of Web-Based Education Given to Parents on Children's İnternet Gaming Disorder

Internet Gaming Disorder (IOB) is an important problem that is increasingly prevalent all over the world and can be prevented before it develops. This research is a single-blind, randomized controlled experimental study to evaluate the effect of Internet-based education given to parents on children's Internet gaming disorder. 96 children and their parents studying in the central districts of a province and at risk for the development of IOBB were divided into intervention (48) and control groups (48) according to the randomization list. The "I know digital games" training consisting of three modules and 10 videos was given to the intervention group via the website prepared by the researchers, and no intervention was made to the control group. The research data were collected at three different times using the "Internet Gaming Disorder Scale Short Form" (İOOBÖ9-SF) and the forms developed by the researchers. In the analysis of data; descriptive statistics, Chi-square, Mann Whitney U test, and repeated measures ANOVA were used. Before the analysis, eight missing data in the control group were estimated with regression estimation models from intent to treat protocols. Statistical significance level p ≤0.05 was taken in all analyzes. Parents and children in the intervention and control groups were similar in terms of sociodemographic characteristics and playing characteristics (p>0.05). It would be beneficial to involve parents in the interventions that nurses will make for primary school children in order to prevent IOB.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Anticipated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
96

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Contact Backup

Study Locations

  • Turkey
    • Antakya
      • Hatay, Antakya, Turkey, 31100
        • Recruiting
        • Meryem MUTLU SAYIN
        • Contact:
          • Sümbüle SÜMBÜLE KÖKSOY VAYISOĞLU

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

9 years to 10 years (Child)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • For kids

    • To have a score between 25-36 from IOOBÖ9-SF [69]
    • Willingness to participate in the study,
    • No communication barrier,
    • Being educated in high socioeconomic level schools,
    • Not having a psychiatric diagnosis and/or not using psychiatric medication

  • for parents

    • Your child's score between 25-36 on IOOBÖ9-SF,
    • Willingness to participate in the study,
    • No communication barrier,
    • Having at least one tablet/smartphone/computer and being able to use these devices,
    • Having mobile or home internet,
    • Being literate,
    • The parent who will participate in the study does not have a psychiatric diagnosis and/or uses psychiatric medication.

Exclusion Criteria:

  • For kids

    • Having received 25 points below or 36 points above IOOBÖ9-SF
    • Not being willing to participate in the study,
    • Having a communication barrier (not being able to speak or understand Turkish…),
    • Having a psychiatric diagnosis and/or using psychiatric medication

  • for parents

    • Your child's score below 25 or above 36 on OOOBÖ9-SF
    • Not being willing to participate in the study,
    • Having a communication barrier (not being able to speak or understand Turkish…)
    • Not having at least one tablet/smartphone/computer,
    • Not having mobile or home internet,
    • Being illiterate,
    • The parent who will participate in the study does not have a psychiatric diagnosis and/or uses psychiatric medication.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: web-based training for parents in the intervention group
Parents were given "I know digital games" training with 10 videos from the website.
Behavioral: web-based "I know digital games" training for intervation grup
"I know digital games" training consisting of 10 web-based videos
Other: parents in the control group
No intervention was applied to the parents in the control group.
Other: The control group was not trained
The control group was not trained

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Internet Gaming Disorder Scale Short Form (IGDS9-SF) score
Time Frame: 4 months
An increase in the scale scores means that the problematic behavior increases. (Min:9; Max:36)
4 months

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Parents' knowledge points on digital games
Time Frame: 4 months
Evaluation of parents' knowledge scores about digital games
4 months
Families' Knowledge, Behavior and Problems Related to Digital Games Evaluation Form scores
Time Frame: 4 months
Evaluation of the scores obtained by parents from the form in the dimensions of "controlling their children's digital games", "protecting them from the harms of digital games", "limiting their digital games", "forcefully controlling (punishing) digital games", "guiding digital games".
4 months
Problems that parents have with their children due to digital games
Time Frame: 4 months
Evaluation of the problems parents experience with their children due to digital games
4 months
children's digital gaming time
Time Frame: 4 months
Evaluation of children's digital game playing time
4 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Mersin University

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Director: Sümbüle Köksoy Vayısoğlu, Mersin University Faculty of Nursing

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
December 1, 2019

Primary Completion (Anticipated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
July 31, 2023

Study Completion (Anticipated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
January 1, 2024

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
November 6, 2022

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
November 18, 2022

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
November 30, 2022

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
March 27, 2023

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 23, 2023

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
March 1, 2023

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • MMUTLU

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Will be shared after the completion of the research reports.

IPD Sharing Time Frame

It can be used for two years after the research reports are uploaded.

IPD Sharing Access Criteria

To be doing research on digital addictions.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings